JPWO2021226576A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021226576A5 JPWO2021226576A5 JP2022567837A JP2022567837A JPWO2021226576A5 JP WO2021226576 A5 JPWO2021226576 A5 JP WO2021226576A5 JP 2022567837 A JP2022567837 A JP 2022567837A JP 2022567837 A JP2022567837 A JP 2022567837A JP WO2021226576 A5 JPWO2021226576 A5 JP WO2021226576A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- antibody
- chain variable
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 70
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 57
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 31
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 210000000066 myeloid cell Anatomy 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims description 8
- 210000003979 eosinophil Anatomy 0.000 claims description 8
- 210000000440 neutrophil Anatomy 0.000 claims description 8
- 210000003630 histaminocyte Anatomy 0.000 claims description 7
- 210000003651 basophil Anatomy 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 4
- 101000835928 Homo sapiens Signal-regulatory protein gamma Proteins 0.000 claims description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 4
- 102100025795 Signal-regulatory protein gamma Human genes 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 4
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims description 3
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000006343 Cutaneous Mastocytosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010048768 Dermatosis Diseases 0.000 claims description 2
- 206010052837 Endocarditis fibroplastica Diseases 0.000 claims description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 2
- 208000019534 Gleich syndrome Diseases 0.000 claims description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 2
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 201000008830 Loeffler endocarditis Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims description 2
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010042342 Subcorneal pustular dermatosis Diseases 0.000 claims description 2
- 208000010265 Sweet syndrome Diseases 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 206010052568 Urticaria chronic Diseases 0.000 claims description 2
- 208000014926 Vesiculobullous Skin disease Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 2
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 206010057271 eosinophilic colitis Diseases 0.000 claims description 2
- 230000002327 eosinophilic effect Effects 0.000 claims description 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 2
- 201000001561 eosinophilic gastritis Diseases 0.000 claims description 2
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 2
- 208000023368 generalized pustular psoriasis Diseases 0.000 claims description 2
- 210000001280 germinal center Anatomy 0.000 claims description 2
- 208000002557 hidradenitis Diseases 0.000 claims description 2
- 230000037417 hyperactivation Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 2
- 208000029081 mast cell activation syndrome Diseases 0.000 claims description 2
- 230000003448 neutrophilic effect Effects 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 230000000552 rheumatic effect Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 201000009324 Loeffler syndrome Diseases 0.000 claims 1
- 206010071282 Mastocytic enterocolitis Diseases 0.000 claims 1
- 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 41
- 238000000034 method Methods 0.000 description 29
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 4
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022309P | 2020-05-08 | 2020-05-08 | |
| US63/022,309 | 2020-05-08 | ||
| PCT/US2021/031541 WO2021226576A1 (en) | 2020-05-08 | 2021-05-10 | Sirp alpha and sirp beta 1 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023525298A JP2023525298A (ja) | 2023-06-15 |
| JPWO2021226576A5 true JPWO2021226576A5 (https=) | 2024-05-20 |
| JP2023525298A5 JP2023525298A5 (https=) | 2024-05-20 |
Family
ID=76197640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567870A Pending JP2023525753A (ja) | 2020-05-08 | 2021-05-10 | Ｓｉｒｐアルファ、ｓｉｒｐベータ１およびｓｉｒｐガンマ抗体、ならびにそれらの使用 |
| JP2022567837A Pending JP2023525298A (ja) | 2020-05-08 | 2021-05-10 | Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567870A Pending JP2023525753A (ja) | 2020-05-08 | 2021-05-10 | Ｓｉｒｐアルファ、ｓｉｒｐベータ１およびｓｉｒｐガンマ抗体、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12503508B2 (https=) |
| EP (2) | EP4146698A1 (https=) |
| JP (2) | JP2023525753A (https=) |
| KR (2) | KR20230017219A (https=) |
| CN (2) | CN115768795A (https=) |
| AU (2) | AU2021267943A1 (https=) |
| CA (2) | CA3177961A1 (https=) |
| GB (2) | GB2613259A (https=) |
| IL (2) | IL298024A (https=) |
| TW (2) | TW202208431A (https=) |
| WO (2) | WO2021226591A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021226591A1 (en) | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
| CN118591619A (zh) * | 2021-11-24 | 2024-09-03 | 雷格细胞股份有限公司 | 人诱导性调节性t细胞及其制作方法 |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN117025547B (zh) * | 2023-10-08 | 2023-12-12 | 迈杰转化医学研究(苏州)有限公司 | 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用 |
| TW202529810A (zh) | 2023-10-19 | 2025-08-01 | 美商電子療法股份有限公司 | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 |
| TW202523701A (zh) | 2023-10-19 | 2025-06-16 | 美商電子療法股份有限公司 | 用於治療癌症之ｓｉｒｐ抗體 |
| WO2025226691A1 (en) | 2024-04-22 | 2025-10-30 | Electra Therapeutics, Inc. | Sirp alpha and beta antibodies for treatment of epstein–barr virus infections |
| CN119192379B (zh) * | 2024-11-22 | 2025-01-28 | 四川省医学科学院·四川省人民医院 | 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| KR20260030924A (ko) * | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| MA47111A (fr) | 2016-12-22 | 2019-10-30 | Univ Wake Forest Health Sciences | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer |
| JP7179743B2 (ja) * | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| CN118271443A (zh) * | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| JP7395471B2 (ja) * | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| EP3802602A1 (en) * | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
| CA3140904A1 (en) | 2019-06-24 | 2020-12-30 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
| US20230340112A1 (en) | 2020-02-28 | 2023-10-26 | Apexigen, Inc. | Anti-sirpa antibodies and methods of use |
| WO2021226591A1 (en) * | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
| WO2023086906A2 (en) | 2021-11-10 | 2023-05-19 | Electra Therapeutics, Inc. | Sirp gamma antibodies and uses thereof |
| TW202523701A (zh) | 2023-10-19 | 2025-06-16 | 美商電子療法股份有限公司 | 用於治療癌症之ｓｉｒｐ抗體 |
| TW202529810A (zh) | 2023-10-19 | 2025-08-01 | 美商電子療法股份有限公司 | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 |
-
2021
- 2021-05-10 WO PCT/US2021/031605 patent/WO2021226591A1/en not_active Ceased
- 2021-05-10 EP EP21729164.0A patent/EP4146698A1/en active Pending
- 2021-05-10 IL IL298024A patent/IL298024A/en unknown
- 2021-05-10 EP EP21730008.6A patent/EP4146699A1/en active Pending
- 2021-05-10 CN CN202180033618.6A patent/CN115768795A/zh active Pending
- 2021-05-10 GB GB2218419.6A patent/GB2613259A/en not_active Withdrawn
- 2021-05-10 AU AU2021267943A patent/AU2021267943A1/en active Pending
- 2021-05-10 CN CN202180033623.7A patent/CN115768796A/zh active Pending
- 2021-05-10 JP JP2022567870A patent/JP2023525753A/ja active Pending
- 2021-05-10 KR KR1020227042951A patent/KR20230017219A/ko active Pending
- 2021-05-10 IL IL297982A patent/IL297982A/en unknown
- 2021-05-10 TW TW110116828A patent/TW202208431A/zh unknown
- 2021-05-10 US US17/923,778 patent/US12503508B2/en active Active
- 2021-05-10 CA CA3177961A patent/CA3177961A1/en active Pending
- 2021-05-10 WO PCT/US2021/031541 patent/WO2021226576A1/en not_active Ceased
- 2021-05-10 CA CA3178038A patent/CA3178038A1/en active Pending
- 2021-05-10 TW TW110116827A patent/TW202208430A/zh unknown
- 2021-05-10 GB GB2218421.2A patent/GB2613464A/en not_active Withdrawn
- 2021-05-10 KR KR1020227042887A patent/KR20230017793A/ko active Pending
- 2021-05-10 US US17/923,781 patent/US20230174648A1/en active Pending
- 2021-05-10 AU AU2021269130A patent/AU2021269130A1/en active Pending
- 2021-05-10 JP JP2022567837A patent/JP2023525298A/ja active Pending
-
2024
- 2024-02-28 US US18/590,865 patent/US12187797B2/en active Active
- 2024-11-27 US US18/963,213 patent/US20250197492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2613259A (en) | SIRP alpha and SIRP beta 1 antibodies and uses thereof | |
| US20230242648A1 (en) | Antibodies to integrin avb6 and use of same to treat cancer | |
| AU2016276751B2 (en) | CD123 antibodies and conjugates thereof | |
| US20210047404A1 (en) | Cd33 antibodies and use of same to treat cancer | |
| AU2023251427A1 (en) | C-kit antibodies | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| US7982017B2 (en) | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same | |
| CN106029697B (zh) | 具有经修饰的ch2-ch3序列的犬抗体 | |
| US8545844B2 (en) | Humanized antibodies against human IL-22RA | |
| KR20210063467A (ko) | Edb 표적화 il-12 조성물 | |
| CN119768425A (zh) | 抗-tl1a抗体及其使用方法 | |
| JP7604401B2 (ja) | 抗体および使用方法 | |
| JPWO2021226576A5 (https=) | ||
| JP2022522815A (ja) | Ｔｓｇ－６抗体およびその用途 | |
| JPWO2021226591A5 (https=) | ||
| US20250051440A1 (en) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling | |
| KR20250112280A (ko) | 항-인간 pd-l1 항체 및 이들의 용도 | |
| CN120380022A (zh) | 抗nkg2a抗体及其用途 | |
| WO2025103425A1 (en) | Multispecific antibodies and uses thereof | |
| US20240360214A1 (en) | LILRB1 and LILRB2 ANTIBODIES AND METHODS OF USE THEREOF | |
| WO2024131849A1 (zh) | Cd38单克隆抗体及其应用 | |
| JPWO2022195028A5 (https=) | ||
| CN120380017A (zh) | 抗-tnfr2抗体及其使用方法 | |
| WO2022103660A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| CN116917330A (zh) | 激活蛋白/TGF-β和RANKL的双功能拮抗剂及其用途 |